BioSpace News Archive

Drug Development

MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

83% overall response rate in patients with relapsed or refractory follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma

June 22, 2019
·
7 min read
BioForest

African American Men in D.C. are at Greater Risk to Develop Kidney Disease

Howard University Chronic Kidney Disease Program Encourages Testing for Men’s Health Month

June 22, 2019
·
3 min read
Deals

CORRECTING and REPLACING Civilization Ventures Announces Portfolio Exit with Acquisition of Singular Bio by Invitae (NYSE: NVTA)

Civilization Ventures is announcing its second portfolio exit in its third year of operations with the acquisition of Singular Bio, a private company developing novel technology for single molecule analysis of DNA, by Invitae, Inc., a publicly traded company at the forefront of the genomics revolution.

June 22, 2019
·
3 min read
Policy

Dr. Reddy’s Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market

Dr. Reddy’s Laboratories Ltd. announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 (Phytonadione) Injectable Emulsion USP, 10 mg/ml, approved by the U.S. Food and Drug Administration.

June 22, 2019
·
3 min read
BioCapital

American Nurses Association Takes Action on Critical Public Health Issues

The representatives of the American Nurses Association Membership Assembly acted on several compelling and critical issues focused on patient care and public health.

June 22, 2019
·
2 min read